hrp0097p1-128 | Growth and Syndromes | ESPE2023

Delayed puberty as a core feature of POLE1: The Irish Experience

Reynolds Claire , Somers Eric , Ann Lynch Sally , Hawkes Colin , Leahy Ronan , M O'Connell Susan , Sherlock Mark

Recently, pathogenic biallelic variants in the gene encoding DNA polymerase epsilon catalytic subunit 1 (POLE1), have been described in 15 individuals from 12 families, including members of 3 Irish families. These loss-of-function mutations cause POLε deficiency, thus impairing DNA replication. All reported cases share the same heterozygous intronic variant (c.1686þ32C>G) as part of a common haplotype, in addition to a different loss-of-function variant in the ot...

hrp0086s5.3 | Mitochondrial dysfunction and endoplasmic reticulum stress in endocrine diseases | ESPE2016

Activation of HSP 72: A Therapeutic Target for Diseases Related to both ER Stress and Mitochondrial Dysfunction

Febbraio Mark

Over the past decade, work from our research group has demonstrated that over-expression or activation of the chaperone protein heat shock protein 72 (HSP72; the inducible form of the 70kDa family of heat shock proteins) in skeletal muscle reduces obesity-induced insulin resistance (for review see). These findings led to the development of the small molecule activator of HSP72, namely BGP-15 which, in pre-clinical studies, has proven to be effective in the treatment of several...

hrp0086p1-p755 | Pituitary and Neuroendocrinology P1 | ESPE2016

Gonadotropin-Releasing Hormone Stimulation Test in Girls Younger than 3 Years Old: Does the Stimulated LH Greater Than 5 IU/l Always Mark Central Puberty Precoccious?

Karabulut Gulcan Seymen , Atar Muge , Cizmecioğlu Filiz , Hatun Şukru

Background: Premature thelarche is the isolated breast development in girls <8 years of age unaccompanied by other signs of puberty including advanced bone age or growth spurt. The GnRH stimulation test is used to distinguish between premature thelarche and central precocious puberty.Objective and hypotheses: We studied accuracy of the gonadotropin responses to GnRH stimulation in predicting pubertal progression in children diagnosed with premature t...

hrp0086p2-p155 | Bone &amp; Mineral Metabolism P2 | ESPE2016

Bisphosphonate Treatment of Hypercalcemia in a Child with Jansen’S Metaphyseal Chondrodysplasia

Sharwood Erin , Harris Mark

Background: Jansen’s Metaphyseal Chondrodysplasia is a rare autosomal dominant condition caused by activating mutations in the parathyroid hormone/parathyroid hormone related peptide receptor (PTH1R). It is associated with persistent PTH-independent hypercalcemia and hypercalciuria from an early age. Our patient, a 2 year old boy with genetically proven Jansen’s Metaphyseal Chondrodysplasia, developed bilateral medullary nephrocalcinosis secondary to persistent hyper...

hrp0089p2-p048 | Bone, Growth Plate &amp; Mineral Metabolism P2 | ESPE2018

Infantile Arterial Calcification and Subsequent Hypophosphatemia due to ENPP1 Mutation – A Case Followed through to Adulthood

Nour Munier , Inman Mark , Arnason Terra

Introduction: Infantile Arterial Calcification (IAC) is a rare and frequently lethal condition. Children who survive the infantile period may develop fibroblast growth factor 23 (FGF23) mediated hypophosphatemia and rickets when IAC is due to mutations in the ENPP1 gene.Case: We present a female patient born to a family whose previous child died at birth with extensive vascular calcifications. Akin to the first sibling, our case presented with e...

hrp0084p3-961 | GH &amp; IGF | ESPE2015

Characterisation of Children Born Small for Gestational Age within the Australian Indications for GH (GH) Therapy: An OZGROW Analysis

Hughes Ian , Harris Mark , Cotterill Andrew

Background: Small for gestational age (SGA) without subsequent catch up growth is an indication for GH treatment in Europe, the US, and Korea but not in Australia. However, many SGA are likely to be included under the ‘short stature and slow growth’ (SSSG) indication. It is unknown to what extent children born SGA are included in the Australian indications or how they differ from non-SGA patients within each indication and gender.Objective and ...

hrp0084fc11.3 | Neuroendocrinology | ESPE2015

Next Generation Sequencing: Towards a new Clinical Frontier in the Diagnosis and Management of Pituitary Tumours

McCabe Mark , Cowley Mark , Tao Jiang , Dias Kerith-Rae , Thompson Tanya , Dinger Marcel , McCormack Ann

Background: In the past few years, new genes involved with familial predisposition to pituitary tumour development have been recognised, including AIP and SDHx. These factors are likely to underestimate the occurrence of familial pituitary tumour predisposition, commonly thought to account for 5% of all pituitary tumours. Furthermore, the clinical management of aggressive pituitary tumours is challenging, particularly when tumours exhibit resistance to standa...

hrp0089p2-p005 | Adrenals and HPA Axis P2 | ESPE2018

Perioperative Care of CAH – Incongruencies of Practices among Canadian Specialists

Nour Munier , Gill Hardave , Mondal Prosanta , Inman Mark , Urmson Kristine

Introduction: In pediatric years, the most common cause of primary adrenal insufficiency is congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Current Endocrine Society guidelines advocate for the use of perioperative supraphysiologic (often referred to as ‘stress dose’) glucocorticoids for children with primary adrenal insufficiency undergoing general anesthesia or surgery. We perceived a difference in practice patterns amongst pediatric subspeci...

hrp0089p3-p356 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P3 | ESPE2018

Paediatric Doctors’ Experience and Knowledge of the Initial Management of Neonatal Ambiguous Genitalia

McGlacken-Byrne Sinead , Byrne Kathryn , O'Rahelly Mark , Ryan Ethel

Introduction: Neonatal ambiguous genitalia can herald sensitive, time-critical, and life-threatening diagnoses and thus paediatric doctors must be competent in their management. However, ambiguous genitalia are rare, limiting clinical exposure. We assessed paediatric doctors’ experience of, knowledge of, and confidence in managing this condition.Methods: A questionnaire was circulated to paediatric doctors at two tertiary and four secondary level pa...

hrp0082p2-d1-518 | Pituitary | ESPE2014

Goliath, a Variant of DAVID Syndrome?

Hasselmann Caroline , Samuels Mark E , Van Vliet Guy

Background: DAVID syndrome (deficit in anterior pituitary function and variable immune deficiency) (J Clin Endocrinol Metab 97 E121, 2012) can be caused by NFKB2 mutations (Am J Hum Genet 93 13, 2013). All patients have an orthotopic posterior pituitary (PP) and most only ACTH deficiency.Objective and Hypothesis: To describe a girl with common variable immunodeficiency (CVID), ectopic PP (EPP) ...